Article
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Breast cancer research : BCR - 13 May 2020
Martínez-Sáez Olga, Chic Nuria, Pascual Tomás, Adamo Barbara, Vidal Maria, González-Farré Blanca, Sanfeliu Esther, Schettini Francesco, Conte Benedetta, Brasó-Maristany Fara, Rodríguez Adela, Martínez Débora, Galván Patricia, Rodríguez Ana Belén, Martinez Antonio, Muñoz Montserrat, Prat Aleix
Abstract excerpt
PURPOSE: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations in BC. This information is critical as patients and clinicians are using this and other genomic assays to indicate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.